ライフサイエンスコーパス: endothelial growth factor

1 high endogenous expression of VEGF (vascular endothelial growth factor).

2 the angiogenic growth factor VEGF (vascular endothelial growth factor).

3 or insulin-like growth factor-I and vascular endothelial growth factor.

4 ibitor of metalloproteinases 1, and vascular endothelial growth factor.

5 ransforming growth factor beta, and vascular endothelial growth factor-1 compared to nonneoplastic du

6 Acting as a partial agonist of vascular endothelial growth factor 2 (VEGFR2), soluble decorin si

7 n to promote vascular leak, such as vascular endothelial growth factor A (VEGF).

8 Vascular endothelial growth factor A (VEGF-A) and its binding to

9 s, which was regulated, in turn, by vascular endothelial growth factor A (VEGF-A) and platelet-derive

10 njections of modified mRNA encoding vascular endothelial growth factor A (VEGF-A) or buffered saline

11 (GLUT-1), erythropoietin (EPO), and vascular endothelial growth factor A (VEGF-A) were analyzed by me

12 wo critical pro-angiogenic factors, vascular endothelial growth factor A (VEGF-A), and VEGF-C.

13 ptional regulator Myc-like (c-myc), vascular endothelial growth factor A (VEGF-A), and Wnt family mem

14 rmeability in CDI mice and elevated vascular endothelial growth factor A (VEGF-A), which was induced

15 tion with Leishmania parasites, the vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 (VE

16 targeting 2 proangiogenic factors, vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (

17 Blockade of vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (

18 Whereas therapies targeting vascular endothelial growth factor A (VEGFA) can suppress leakage

19 yc and transcriptionally repressing vascular endothelial growth factor A (VEGFA) expression.

20 on of proangiogenic factors such as vascular endothelial growth factor A (VEGFA) has had limited clin

21 Vascular endothelial growth factor A (VEGFA) stimulates angiogene

22 s, producing a correlative level of vascular endothelial growth factor A (VEGFA) to define a resident

23 epletion increased basal as well as vascular endothelial growth factor A (VEGFA)- and ANG1/2-stimulat

24 thiocyanate-dextran), and prevented vascular endothelial growth factor A (VEGFA)-induced barrier brea

25 phagic degradation of intracellular vascular endothelial growth factor A (VEGFA).

26 Inhibition of vascular endothelial growth factor A (VEGFA)/vascular endothelial

27 ascular endothelial growth factor-A vascular endothelial growth factor A [VEGF-A], and terminal deoxy

28 AA and BB; placental growth factor; vascular endothelial growth factor A and D; vascular endothelial

29 we demonstrate the efficacy of anti-vascular endothelial growth factor A blockade for prohibiting TAM

30 laudin-1, occludin, E-cadherin, and vascular endothelial growth factor A levels; Masson trichrome sta

31 cardium, thereby diminishing Vegfa (vascular endothelial growth factor A) interaction with HS.

32 1 alpha, glucose transporter 1, and vascular endothelial growth factor A).

33 tion of its transcriptional target, vascular endothelial growth factor A, in clodronate-treated tumor

34 Vascular endothelial growth factor-A (VEGF) is the angiogenic fac

35 Vascular endothelial growth factor-A (VEGF) plays a critical role

36 Here we show that vascular endothelial growth factor-A (VEGF-A) and platelet-derive

37 associated with reduced hippocampal vascular endothelial growth factor-A (VEGF-A) in both male and fe

38 ifically whether macrophage-derived vascular endothelial growth factor-A (Vegf-A) is crucial to estab

39 VWF binds to several GFs, including vascular endothelial growth factor-A (VEGF-A) isoforms and platel

40 HNSCC cells of invaded lymph nodes, vascular endothelial growth factor-A (VEGF-A), vascular endotheli

41 tibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab i

42 g cause of this regulation, via the vascular endothelial growth factor-A (VEGF-A)/VEGF receptor 2 (VE

43 cardiac endothelial cells increases vascular endothelial growth factor-A expression and enhances thei

44 In addition, vascular endothelial growth factor-A levels were negatively corre

45 nsforming growth factor-beta(1) and vascular endothelial growth factor-A secretion was measured in se

46 gy, and imunnohistochemistry (Ki67, vascular endothelial growth factor-A vascular endothelial growth

47 ions largely independent of VEGF-A (vascular endothelial growth factor-A).

48 macrophage inflammatory protein-3a, vascular endothelial growth factor-A, and IL-1RA production in BA

49 transforming growth factor-beta(1), vascular endothelial growth factor-A/C, and cAMP/ERK expression w

50 ected with adeno-associated virus 1-vascular endothelial growth factor-A165 under control of a hypoxi

51 neuraminidase-treated IgG inhibited vascular endothelial growth factor activation of endothelial NO s

52 Anti-vascular endothelial growth factor acts faster than laser therapy

53 ix by following external gradients of Vessel Endothelial Growth Factor, adhesion and stiffness, which

54 ervation (n = 1), intravitreal anti-vascular endothelial growth factor agents (n = 4), vitrectomy (n

55 Intravitreous injections of antivascular endothelial growth factor agents are effective for treat

56 te increasing worldwide use of anti-vascular endothelial growth factor agents for treatment of retino

57 ntial differential efficacy of anti-vascular endothelial growth factor agents in the treatment of DME

58 Treatment with anti-vascular endothelial growth factor agents.

59 relied on secretion of the cytokine vascular endothelial growth factor alpha (VEGF-alpha) by a minor

60 l bone level and the expressions of vascular endothelial growth factor and core-binding factor subuni

61 ally, TO reduced gene expression of vascular endothelial growth factor and surfactant protein A and B

62 cells (BECs) secreted higher VEGF (vascular endothelial growth factor) and lower TSP-1 (thrombospond

63 asurements of HIF-1a, HIF-2a, VEGF (vascular endothelial growth factor), and eNOS (endothelial nitric

64 our patients were treated with anti-vascular endothelial growth factor, and 21 patients were treated

65 include fibroblast growth factor-2, vascular endothelial growth factor, and apolipoprotein-D.

66 eceptor-associated tyrosine kinase, vascular endothelial growth factor, and cell cycle pathways, wher

67 coding genes involved in metabolic, vascular endothelial growth factor, and extracellular signal-regu

68 platelet-derived growth factor-AA, vascular endothelial growth factor, and others) were found betwee

69 factors (fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth f

70 ch as interferon-gamma (IFN-gamma), vascular endothelial growth factor, and soluble vascular cell adh

71 ukin]-12, IL-17, IL-10, IL-7, VEGF [vascular endothelial growth factor]), and cluster 4 (n=37; IL-8,

72 Anti-vascular endothelial growth factor (anti-VEGF) drugs can cause ph

73 sentation; (3) no intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection before p

74 was primarily driven by use of anti-vascular endothelial growth factor (anti-VEGF) injections from 20

75 y, laser photocoagulation, and anti-vascular endothelial growth factor (anti-VEGF) treatment.

76 ive AMD eyes and the impact of anti-vascular endothelial growth factor (anti-VEGF) treatments or geog

77 wing intravitreal injections of antivascular endothelial growth factor (anti-VEGF).

78 Inadequate tumor uptake of the vascular endothelial growth factor antibody bevacizumab could exp

79 suggest that a rise in intraocular vascular endothelial growth factor as a consequence of mild perip

80 with a significant decrease in free vascular endothelial growth factor but was associated with increa

81 Adeno-associated virus 8-vascular endothelial growth factor C (AAV8-VEGF-C) was injected i

82 However, ectopic expression of vascular endothelial growth factor C (VEGF-C) promotes enhanced p

83 te that the lymphangiogenic factors vascular endothelial growth factor C (VEGFC) and VEGFD are cleave

84 Vascular endothelial growth factor-C (VEGF-C) acts primarily on e

85 d a feedback loop between PROX1 and vascular endothelial growth factor-C (VEGF-C) signaling.

86 dothelial growth factor-A (VEGF-A), vascular endothelial growth factor-C (VEGF-C) were positive contr

87 identified a critical function for vascular endothelial growth factor-C (VEGF-C), that of maintainin

88 In the adult brain, vascular endothelial growth factor D (VEGFD) is required for stru

89 rs prostate specific antigen (PSA), vascular endothelial growth factor-D (VEGF-D), ETS-related gene p

90 Up-regulation of vascular endothelial growth factor enhances the therapeutic effec

91 nd a link between hypoxia-dependent vascular endothelial growth factor expression in tumor diversity

92 lammatory program by CD1d-dependent vascular endothelial growth factor expression.

93 on of pro-angiogenic factors VEGFA (vascular endothelial growth factor), FGF2 (fibroblast growth fact

94 leasing insulin growth factor 1 and vascular endothelial growth factor, followed by intramyocardial i

95 Vascular endothelial growth factor has emerged as a significant c

96 Although VEGF (vascular endothelial growth factor) improves lung structure and f

97 vels and mesenchymal cells, but not vascular endothelial growth factor in Hyal2(-/-) embryonic hearts

98 ealed elevated levels of angiogenic vascular endothelial growth factor in the clopidogrel group.

99 ht the need for therapy beyond anti-vascular endothelial growth factor inhibition to address fibrosis

100 vorinostat combined with either the vascular endothelial growth factor inhibitor pazopanib (NCT013398

101 more prior regimens that included a vascular endothelial growth factor inhibitor.

102 Vascular endothelial growth factor-inhibitor (VEGF-I) therapy in

103 t experiences specific to receiving vascular endothelial growth factor inhibitors (anti-VEGF) for wet

104 raised that intravitreal dosing of vascular endothelial growth factor inhibitors in DME could be ass

105 to treatment with intravitreal anti-vascular endothelial growth factor injection was observed in 4 pa

106 lar degeneration receiving >=1 anti-vascular endothelial growth factor injection(s) from January 1, 2

107 103mum; P = 0.527), number of anti-vascular endothelial growth factor injections (6.5 +/- 2.5 vs. 6.

108 They were given retreatment anti-vascular endothelial growth factor injections according to predet

109 Subsequently, anti-vascular endothelial growth factor injections and panretinal phot

110 n: Eyes receiving intravitreal anti-vascular endothelial growth factor injections from July 1, 2013,

111 intervention requiring 1 or 2 anti-vascular endothelial growth factor injections only.

112 performing either intravitreal anti-vascular endothelial growth factor injections or posterior segmen

113 including some combination of anti-vascular endothelial growth factor injections, photodynamic thera

114 a receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections.

115 o had received 2 or more prior anti-vascular endothelial growth factor intravitreal injections and we

116 indicative of persistently elevated vascular endothelial growth factor levels and an early indicator

117 Modulation of vascular endothelial growth factor-mediated immune suppression vi

118 han as a result of exposure to anti-vascular endothelial growth factor medications.

119 y; similar to results obtained with vascular endothelial growth factor neutralization.

120 ing intravitreal injections of anti-vascular endothelial growth factor or verteporfin photodynamic th

121 s based mainly on inhibition of the vascular endothelial growth factor pathway.

122 pendent of its interaction with CD81 leading endothelial growth factor receptor (EGFR) activation.

123 heckpoint inhibitor therapy include vascular endothelial growth factor receptor (VEGF-R) tyrosine kin

124 that constitutively express soluble vascular endothelial growth factor receptor (VEGFR) 3-Ig in the s

125 We then measured vascular endothelial growth factor receptor (VEGFR) expression in

126 enal tumour cell vaccine and of the vascular endothelial growth factor receptor (VEGFR) tyrosine kina

127 sion in metastatic RCC treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kina

128 coordinately process controlled by vascular endothelial growth factor receptor (VEGFR)-Notch signali

129 b blocks VEGF-A-induced endothelial vascular endothelial growth factor receptor 1 (VEGFR1) activation

130 omputational methods predicted that Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) could be o

131 rmation (evidenced by a decrease in vascular endothelial growth factor receptor 1 positive (VEGFR1(+)

132 endothelial growth factor A and D; vascular endothelial growth factor receptor 1, 2, and 3; osteopon

133 riggering apoptosis, and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2) in endoth

134 aling event, m-SCF/c-Kit and VEGF-A/vascular endothelial growth factor receptor 2 (VEGFR-2), contribu

135 l cells to suppress the activity of vascular endothelial growth factor receptor 2 (VEGFR2) and promot

136 Vascular endothelial growth factor receptor 2 (VEGFR2) controls a

137 Vascular endothelial growth factor receptor 2 (VEGFR2) localized

138 late the crosstalk between IL-6 and vascular endothelial growth factor receptor 2 (VEGFR2) signaling

139 endothelial growth factor A (VEGFA)/vascular endothelial growth factor receptor 2 (VEGFR2) signaling

140 phage recruitment after injury; (2) vascular endothelial growth factor receptor 2 (VegfR2) signaling;

141 ex a slightly reduced expression of vascular endothelial growth factor receptor 2 (VEGFR2) was establ

142 f endothelial glycoproteins such as vascular endothelial growth factor receptor 2 (VEGFR2) with siali

143 validate KDR, which encodes for the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), as a nove

144 EGFR)-EPH receptor A2 (EPHA2), EGFR-vascular endothelial growth factor receptor 2 (VEGFR2), EPHA2-VEG

145 d leukocyte recruitment by engaging vascular endothelial growth factor receptor 2 (VEGFR2), which was

146 Glycocalyx regulation of vascular endothelial growth factor receptor 2 activity.

147 Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonist-plus doc

148 /PGFD mice, conditional deletion of vascular endothelial growth factor receptor 2 in vascular endothe

149 dothelial nitric oxide synthase/Akt/vascular endothelial growth factor receptor 2 signaling, and a re

150 he combination of anti-TLR2 and antivascular endothelial growth factor receptor 2 yielded an additive

151 nd subsequent activation of VEGFR2 (vascular endothelial growth factor receptor 2) and decreases bloo

152 tor 2), and their receptors VEGFR2 (vascular endothelial growth factor receptor 2) and FGFR1 (fibrobl

153 ceptor 1), neuropilin-1 and VEGFR2 (vascular endothelial growth factor receptor 2), whereas in the ad

154 on VEGF(165)b's role in inhibiting vascular endothelial growth factor receptor 2-dependent angiogene

155 of EC markers (VE-cadherin, VEGFR2 [vascular endothelial growth factor receptor 2], or VWF [von Wille

156 rs (prospero homeobox protein 1 and vascular endothelial growth factor receptor 3) as well as blood e

157 ibition plus agents that target the vascular endothelial growth factor receptor and a shift in the cu

158 eneca, Cheshire, United Kingdom), a vascular endothelial growth factor receptor and platelet-derived

159 CN transgenic mice treated with the vascular endothelial growth factor receptor inhibitor cediranib.

160 assist in identifying responders to vascular endothelial growth factor receptor tyrosine kinase inhib

161 -of-action complementary to VEGF-R (vascular endothelial growth factor receptor)-targeted therapies.

162 ization with other receptors, such as CXCR4, endothelial growth factor receptor, or the alpha (1)-adr

163 that GREM1 can bind to and activate vascular endothelial growth factor receptor-2 (VEGFR2) in endothe

164 cotargeting polo-like kinase 1 and vascular endothelial growth factor receptor-2, Ang-3I-NM@siRNA sh

165 Vascular endothelial growth factor receptor-3 (VEGFR3) signalling

166 vascular endothelial growth factor-vascular endothelial growth factor receptor-mediated angiogenic s

167 and separation of the cell surface vascular endothelial growth factor receptors (VEGFR) in live cell

168 ved in endothelial function include vascular endothelial growth factor receptors (VEGFRs) and G prote

169 Recently, quantification of vascular endothelial growth factor receptors (VEGFRs) provided im

170 isting of PECAM-1, VE-cadherin, and vascular endothelial growth factor receptors (VEGFRs) that reside

171 ine kinase activity associated with vascular endothelial growth factor receptors 1, 2, and 3, current

172 llary density, vessel diameter, and vascular endothelial growth factor signaling to nondiabetic level

173 Delivery of siRNA against vascular endothelial growth factor (siVEGF) at extremely low conc

174 al growth factor homology domain 2, vascular endothelial growth factor, soluble fms-like tyrosine kin

175 To evaluate if the up-regulation of vascular endothelial growth factor strengthens the protective eff

176 ls (sprocs) from the bone marrow by vascular endothelial growth factor-stromal cell-derived factor-1

177 aches, including the use of soluble vascular endothelial growth factor (sVEGF)-VEGF165, have been dev

178 Participants who received antivascular endothelial growth factor therapies for neovascular AMD

179 tment and if eyes treated with anti-vascular endothelial growth factor therapy are at risk of similar

180 Information on the effect of anti-vascular endothelial growth factor therapy in eyes with diabetic

181 n improvements when consistent anti-vascular endothelial growth factor therapy is maintained over a l

182 Anti-vascular endothelial growth factor therapy results in better shor

183 ular edema requiring bilateral anti-vascular endothelial growth factor therapy were included.

184 oximates that of intravitreous anti-vascular endothelial growth factor therapy.

185 Although anti-VEGF (vascular endothelial growth factor) therapy offers short-term ben

186 ed monoclonal antibody that targets vascular endothelial growth factor, to platinum-based chemotherap

187 ral RVO who might benefit from anti-vascular endothelial growth factor treatment were eligible for pa

188 y relevant human alpha-thrombin and vascular endothelial growth factor using changes in concentration

189 ngiopoietin-2/angiopoietin-1 ratio, vascular endothelial growth factor, vascular cell adhesion molecu

190 Other than vascular endothelial growth factor-vascular endothelial growth fa

191 ed to bind a key signaling protein, vascular endothelial growth factor (VEGF(165)), functions in vivo

192 r responders had increased baseline vascular endothelial growth factor (VEGF) (880.0 pg/mL vs 245.4 p

193 Elevated levels of vascular endothelial growth factor (VEGF) A are thought to cause

194 following 3 loading doses of anti- vascular endothelial growth factor (VEGF) agents, and the anatomi

195 iogenesis through the expression of vascular endothelial growth factor (VEGF) and can be induced by t

196 MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth f

197 Vascular endothelial growth factor (VEGF) and placental growth fa

198 Vascular endothelial growth factor (VEGF) and semaphorin-binding

199 ggered by the angiogenesis inducers Vascular Endothelial Growth Factor (VEGF) and Sphingosine-1 Phosp

200 ucible factor-1 alpha (HIF-1alpha), vascular endothelial growth factor (VEGF) and tumor necrosis fact

201 HDM-induced expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 pro

202 Here, we uncovered vascular endothelial growth factor (VEGF) as a novel inducer of E

203 Vascular endothelial growth factor (VEGF) contributes to blood-re

204 (SIS) immobilized with heparin and vascular endothelial growth factor (VEGF) could be implanted into

205 ment frequency and switches in anti-vascular endothelial growth factor (VEGF) drug.

206 The increases in vascular endothelial growth factor (VEGF) expression and endothel

207 not that of TWIST1 alone, enhanced vascular endothelial growth factor (VEGF) expression via the recr

208 or microvascular density (MVD), and vascular endothelial growth factor (VEGF) expression) from 9 pati

209 of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) has transformed therapy

210 other LPS-induced factors including vascular endothelial growth factor (VEGF) in both cell types.

211 cadherin reporter demonstrated that vascular endothelial growth factor (VEGF) induces VE-cadherin exp

212 5-3335, aflibercept-an FDA-approved vascular endothelial growth factor (VEGF) inhibitor, or a combina

213 e supports the safety of suspending vascular endothelial growth factor (VEGF) inhibitors for neovascu

214 nonpersistence to intravitreal anti-vascular endothelial growth factor (VEGF) injection therapy for n

215 Intravitreal anti-vascular endothelial growth factor (VEGF) injections are used com

216 llowed on a monthly basis with anti-vascular endothelial growth factor (VEGF) injections when needed

217 es frequent intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) injections, which place

218 Vascular endothelial growth factor (VEGF) is a key regulator of a

219 Vascular endothelial growth factor (VEGF) is an angiogenic factor

220 Vascular endothelial growth factor (VEGF) is associated with the

221 Vascular endothelial growth factor (VEGF) is essential for angiog

222 Vascular endothelial growth factor (VEGF) is implicated in the pe

223 demyelinating neuropathy with serum vascular endothelial growth factor (VEGF) more accurately identif

224 our knowledge) the critical role of vascular endothelial growth factor (VEGF) on thymic morphogenesis

225 Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy has bec

226 Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy plays a

227 leomycin treatment was dependent on vascular endothelial growth factor (Vegf) receptor 3 signaling, b

228 as a negative feedback regulator of vascular endothelial growth factor (VEGF) receptor activation.

229 BafA interacts with vascular endothelial growth factor (VEGF) receptor-2 and activate

230 We also show how vascular endothelial growth factor (VEGF) regulates PRKCB promote

231 Because deficiency of vascular endothelial growth factor (VEGF) results in thrombotic m

232 screening interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) secreted from suspended

233 rther demonstrate the importance of Vascular Endothelial Growth Factor (VEGF) secretion for this path

234 ial resistance, predicted polarized vascular endothelial growth factor (VEGF) secretion, and matched

235 F), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) showed time-dependent d

236 e (RTK) inhibitor sunitinib, target vascular endothelial growth factor (VEGF) signaling in cancers.

237 Vascular endothelial growth factor (VEGF) signaling in tumor cell

238 ling transducers and isoforms along vascular endothelial growth factor (VEGF) signaling pathways at c

239 Recently, it was shown that vascular endothelial growth factor (VEGF) signaling plays an impo

240 Here, we showed that vascular endothelial growth factor (VEGF) signaling within the gl

241 he skeletogenic cells controlled by vascular endothelial growth factor (VEGF) signaling.

242 are uniquely sensitive to increased vascular endothelial growth factor (VEGF) stimulation due to a re

243 odynamic therapy (PDT) and (2) anti-vascular endothelial growth factor (VEGF) therapies, which are no

244 .3% were receiving intravitreal antivascular endothelial growth factor (VEGF) therapy (median of 15 i

245 years for patients initiating anti-vascular endothelial growth factor (VEGF) therapy for PDR.

246 Anti-vascular endothelial growth factor (VEGF) therapy has been shown

247 Anti-vascular endothelial growth factor (VEGF) therapy has demonstrate

248 This study assessed anti-vascular endothelial growth factor (VEGF) therapy intensity and i

249 tely 50% of patients receiving anti-vascular endothelial growth factor (VEGF) therapy show significan

250 ced bladder cancer cells to secrete vascular endothelial growth factor (VEGF) through activating Ras

251 effects of continuing the same anti-vascular endothelial growth factor (VEGF) treatment among patient

252 generation (nAMD) who received anti-vascular endothelial growth factor (VEGF) treatment for macular n

253 Anti-vascular endothelial growth factor (VEGF) treatment of neovascula

254 aseline visual acuity (VA) and anti-vascular endothelial growth factor (VEGF) treatment patterns in n

255 lar degeneration (nAMD) during anti-vascular endothelial growth factor (VEGF) treatment.

256 Predictors of anti-vascular endothelial growth factor (VEGF) use and number of anti-

257 s (sGAG) influence the interplay of vascular endothelial growth factor (VEGF)(165) and its heparin-bi

258 rating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), and osteopontin (OPN)

259 mmalian target of rapamycin (mTOR), vascular endothelial growth factor (VEGF), and WNT signaling.

260 ayed robust and stable secretion of vascular endothelial growth factor (VEGF), brain-derived neurotro

261 rmal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), etc.

262 cell-derived factor 1 (SDF-1alpha), vascular endothelial growth factor (VEGF), hypoxia-inducible fact

263 Vascular endothelial growth factor (VEGF), Interleukin 6 (IL-6),

264 giogenic and neurotrophic cytokine, vascular endothelial growth factor (VEGF), is suppressed to abnor

265 otein 10, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), monocyte chemoattracti

266 ters of HIF target genes, including vascular endothelial growth factor (VEGF), where it enhances loca

267 Vascular endothelial growth factor (VEGF), which drives angiogene

268 Vascularisation is dependent upon vascular endothelial growth factor (VEGF), which drives both angi

269 Vascular endothelial growth factor (VEGF)-A has been implicated i

270 Clinical trials aimed at inducing vascular endothelial growth factor (VEGF)-A levels, a potent proa

271 Alternate splicing in the exon-8 of vascular endothelial growth factor (VEGF)-A results in production

272 ell proliferation by regulating the vascular endothelial growth factor (VEGF)-A, VEGF-C, FGFR3, and p

273 release the proangiogenic mediator vascular endothelial growth factor (VEGF)-A.

274 OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D.

275 ls, von Willebrand factor (vWF) and vascular endothelial growth factor (VEGF)-C expression were measu

276 Herein, we identified that vascular endothelial growth factor (VEGF)-C, a potent lymphangiog

277 Vascular endothelial growth factor (VEGF)-D is capable of inducin

278 line-inducible expression of murine vascular endothelial growth factor (VEGF)-D under a tightly contr

279 roles of GIPCs beyond those of the Vascular Endothelial Growth Factor (VEGF)-dependent, proangiogeni

280 e receptors (S1PRs), which restrain vascular endothelial growth factor (VEGF)-induced angiogenesis, s

281 Furthermore, vascular endothelial growth factor (VEGF)-induced EC migration wa

282 For example, vascular endothelial growth factor (VEGF)-mediated angiogenesis i

283 ted with intravitreal injections of vascular endothelial growth factor (VEGF)-neutralizing antibodies

284 hymus-derived regulatory T cells to vascular endothelial growth factor (VEGF)-producing tumors.

285 nied by complete absence of hepatic vascular endothelial growth factor (VEGF)-stromal cell-derived fa

286 yrosine kinase agonists insulin and Vascular Endothelial Growth Factor (VEGF).

287 duration of angiogenesis induced by vascular endothelial growth factor (VEGF).

288 , is driven by chronic elevation of vascular endothelial growth factor (VEGF).

289 morphogenetic protein 2 (BMP-2) and vascular endothelial growth factor (VEGF).

290 ived growth factor-BB (PDGF-BB) and vascular endothelial growth factor (VEGF-165), integrate with gla

291 eriodontal diseases, supported with vascular endothelial growth factor (VEGF-A) and tumor necrosis fa

292 ducible factor-1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF-A), and clinical paramet

293 le initial treatments for DME (anti-vascular endothelial growth factor [VEGF], focal laser treatment,

294 ion of ISL2, the angiogenic markers vascular endothelial growth factor (VEGFA) and CD31 and the proli

295 ells where it was shown to modulate vascular endothelial growth factor (VEGFR)-2 and epidermal growth

296 h-molecular-weight kininogen (cHK), vascular endothelial growth factors (VEGFs), angiopoietins (Angs)

297 al growth factor homology domain 2, vascular endothelial growth factor, von Willebrand factor, E-sele

298 examined (n = 27) with 1 exception (vascular endothelial growth factor) were overexpressed with BAL n

299 0.6 intravitreal injections of anti-vascular endothelial growth factor without significant improvemen

300 erleukin 1 receptor antagonist, and vascular endothelial growth factor) without significant changes i